Martin Correa, MD
Allergy & Immunology · Silver Spring, MDNPI 1255395620
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.2% of the total across 382 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 18.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $2,241 and has fallen 70.7% since, to $657 in 2025.
Across 382 payments — averaging $22.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Regeneron Healthcare Solutions, Inc.$1K
- GSK$1K
- Sanofi$540
- Optinose US, Inc.$469
- Amgen$459
- plus $3K from 30 others
What the payments were for
- Food & beverage$8,25597%
- Education$2383%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 74 | $1,583 |
| Regeneron Healthcare Solutions, Inc. | 40 | $1,224 |
| GSK | 62 | $1,173 |
| Sanofi | 21 | $540 |
| Optinose US, Inc. | 24 | $469 |
| Amgen(2 entities) | 19 | $459 |
| Pfizer | 19 | $395 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $355 |
| Grifols USA, LLC | 17 | $299 |
| Pharming Healthcare, Inc. | 12 | $279 |
| Kaleo, Inc. | 13 | $278 |
| Teva Pharmaceuticals USA, Inc. | 14 | $213 |
| Novartis | 7 | $166 |
| Boehringer Ingelheim | 7 | $158 |
| Genentech USA, Inc. | 5 | $117 |
| Blueprint Medicines Corporation | 4 | $109 |
| Aimmune Therapeutics, Inc. | 4 | $80 |
| Biocryst US Sales Co., LLC | 3 | $74 |
| Aytu Biopharma, Inc. | 2 | $50 |
| Phadia US Inc. | 2 | $47 |
| Incyte Corporation | 2 | $46 |
| CSL Behring | 2 | $43 |
| Hikma Pharmaceuticals USA | 2 | $38 |
| Alk-abello, Inc | 2 | $31 |
| Lilly USA, LLC | 1 | $28 |
| Aerin Medical Inc. | 1 | $27 |
| Tersera Therapeutics LLC | 1 | $25 |
| USWM, LLC | 1 | $25 |
| Mylan Specialty L.p. | 1 | $24 |
| Verona Pharma, Inc. | 1 | $24 |
| Greer Laboratories, Inc. | 1 | $21 |
| Neos Therapeutics, LP | 1 | $21 |
| AbbVie | 1 | $21 |
| Organon | 1 | $19 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $16 |
| Merck | 1 | $15 |
How this compares
$8,493 in reported general payments places this provider in the 75th percentile of 105 allergy & immunology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent SyringeDupilumab | 14 | $49,497 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 20 | $28,557 |
| Wixela InhubFluticasone Propion/Salmeterol | 19 | $4,385 |
| SymbicortBudesonide/Formoterol Fumarate | 19 | $4,163 |
| Azelastine-FluticasoneAzelastine/Fluticasone | 36 | $4,140 |
| Azelastine Hcl | 77 | $3,222 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 13 | $2,337 |
| Levocetirizine Dihydrochloride | 135 | $2,132 |
| Epinephrine | 11 | $1,519 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 41 | $1,452 |
| Fluticasone Propionate | 54 | $1,279 |
| Tacrolimus | 12 | $1,217 |
| Montelukast Sodium | 70 | $823 |
| Triamcinolone Acetonide | 70 | $818 |
| Desloratadine | 22 | $790 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $1,173 | $28,55720 claims |
| AstraZenecaSymbicort | $1,583 | $4,16319 claims |
| Hikma Pharmaceuticals USAEpinephrine | $38 | $1,51911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 105 allergy & immunology providers in Maryland.
Other allergy & immunology in Silver Spring
- Angela CanadySilver Spring$15K
- Jenni YoonSilver Spring$3K
- Vasif KalfaSilver Spring$3K
- Nkiruka ErekosimaSilver Spring$3K
- Djahna ThomasSilver Spring$2K
- Antoine AzarBaltimore$612K
- Mark ScarupaWheaton$508K
- Sally BaileyBaltimore$344K
- Manav SinglaWhite Marsh$168K
- Sudhir SekhsariaRockville$87K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.